Afamelanotide and NB-UVB Light

Phase 3Small molecule

CClinuvel, Inc.

Afamelanotide and NB-UVB Light is one of 36 small molecule programs targeting Vitiligo. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

VitiligoActive, not recruiting

VitiligoPhase 3

Active, not recruiting

Competition

Competitive Landscape

103 competitors in Vitiligo

#DrugCompanyPhaseTrials

Rinvoq

AbbVie

Phase 3

3 2

Opzelura

Pfizer

Phase 3

2 3

Prograf

VVeloxis Pharmaceuticals

Phase 3

8 4

Povorcitinib

Incyte

Phase 3

2 5

Olumiant

Eli Lilly

Phase 2

3 6

Saphnelo

AstraZeneca

Phase 2

1 7

Enbrel

IImmunex

Phase 2

1 8

Kenalog

BBassett Healthcare

Phase 2

1 9

Zocor

OOrganon and Co

Phase 2

1 10

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Vitiligo1 trial

A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo

Active, not recruiting·CClinuvel, Inc.·Phase 3·NCT06109649·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Afamelanotide and NB-UVB Light. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Afamelanotide and NB-UVB Light compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Afamelanotide and NB-UVB Light. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Clinuvel, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CClinuvel, Inc.

Afamelanotide and NB-UVB Light

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Vitiligo1 trial

References

Drug Info

Quick Facts

Related News